Background and aims: There is a bidirectional relationship between obesity and psoriasis. Liraglutide has been shown to improve the severity of psoriatic lesions in patients with type 2 diabetes. We aimed to study the effects of liraglutide 3mg in patients with obesity and psoriasis.Methods: Twenty patients started treatment with liraglutide 3mg for 3 months. Severity of the lesions was evaluated using the Psoriasis Area Severity Index (PASI) and the visual analogue scale of pain (VAS), and quality of life with the Dermatology Quality Index (DLQI).Results: There was a significant reduction in BMI (38.9 +/- 5.8 vs. 36.4 +/- 5.6; p<0.001), CRP (4.5 +/- 2.4 vs. 3 +/- 2mg/L; p<0.01), homocysteine (13.3 +/- 3.6 vs. 11.9 +/- 3 mu mol/L; p<0.01), ferritin (185.4 +/- 142.2 vs. 97.43 +/- 114.4ng/mL; p=0.04) and plasma cortisol (12 +/- 3.1 vs. 11.6 +/- 2.2 mu g/dL, p=0.04). PASI (10 +/- 8.4 vs. 5.1 +/- 6; p<0.0001), VAS (4.1 +/- 2 vs. 2.3 +/- 0.92; p=0.009) and DLQI (12.7 +/- 7 vs. 6.4 +/- 5.6, p<0.0001) improved significantly. In multiple regression analysis, weight loss did not correlate with any inflammatory parameter or PASI.Conclusions: Liraglutide 3mg for three months is effective and safe in reducing weight and improving psoriatic lesions among patients with psoriasis and obesity. Besides, there is an improvement in psoriatic lesions regardless of weight loss that deserves further studies.
